12:00 AM
Jun 28, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Varespladib methyl: Phase III started

Anthera began the double-blind, placebo-controlled, international Phase III VISTA-16 trial to evaluate 500 mg oral varespladib given once daily for 16 weeks in up to 6,500 high-risk patients. Enrollment will be stopped after 395 events...

Read the full 153 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >